Literature DB >> 14713917

Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection.

Marc Beyer1, Holger Bartz, Katharina Hörner, Sandra Doths, Cordula Koerner-Rettberg, Jürgen Schwarze.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) bronchiolitis in infants can lead to wheezing and early allergic sensitization. In mice, RSV infection enhances allergic airway inflammation and airway hyperresponsiveness. Dendritic cells are critical in inducing T-cell responses to both viruses and allergens and could be pivotal in regulating interactions between these.
OBJECTIVE: This study addresses the effects of RSV infection on phenotype and function of pulmonary dendritic cells.
METHODS: BALB/c mice were infected with RSV, and expression of CD11c, MHC II, and CD86 on lung and spleen cells was monitored by flow cytometry for 21 days after infection. CD11c(+) cells were isolated to assess their phagocytic capacity and their ability to induce proliferation in allogenic T cells.
RESULTS: Numbers of pulmonary CD11c(+) MHC II(hi) cells increased 13-fold starting from day 6 after RSV infection. This was associated with increased CD86 expression, reduced phagocytosis, and increased allogenic T-cell stimulatory capacity in CD11c(+) cells. These changes in the lung outlasted acute infection and were not observed in spleens.
CONCLUSION: RSV infection results in sustained increases in numbers of mature dendritic cells in the lung. These might well contribute to the development of intense airway inflammation and airway hyperresponsiveness after RSV infection and to enhancement of subsequent responses to allergen exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14713917     DOI: 10.1016/j.jaci.2003.10.057

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  49 in total

1.  Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2.

Authors:  Allison T Thiele; Tina L Sumpter; Joanna A Walker; Qi Xu; Cheong-Hee Chang; Robert L Bacallao; Rajesh Kher; David S Wilkes
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 2.  Respiratory dendritic cells: mediators of tolerance and immunity.

Authors:  Ryan A Langlois; Kevin L Legge
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection.

Authors:  Daniel S McDermott; Kayla A Weiss; Cory J Knudson; Steven M Varga
Journal:  Future Virol       Date:  2011-08       Impact factor: 1.831

5.  Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand.

Authors:  Junyan Han; Azzeddine Dakhama; Yi Jia; Meiqin Wang; Wanjiang Zeng; Katsuyuki Takeda; Yoshiki Shiraishi; Masakazu Okamoto; Steven F Ziegler; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

6.  Subversion of pulmonary dendritic cell function by paramyxovirus infections.

Authors:  Antonieta Guerrero-Plata; Deepthi Kolli; Chao Hong; Antonella Casola; Roberto P Garofalo
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 7.  The pharmacological modulation of allergen-induced asthma.

Authors:  L L Ma; Paul M O'Byrne
Journal:  Inflammopharmacology       Date:  2012-10-25       Impact factor: 4.473

8.  Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells.

Authors:  Pablo A González; Carolina E Prado; Eduardo D Leiva; Leandro J Carreño; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

9.  Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A.

Authors:  Francis J Martin; Marisa I Gomez; Dawn M Wetzel; Guido Memmi; Maghnus O'Seaghdha; Grace Soong; Christian Schindler; Alice Prince
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

10.  Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.

Authors:  Asunción Mejías; Octavio Ramilo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.